Stockreport

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local treatmen [Read more]